Translating scientific breakthroughs into first-in-class treatments

Novel insights into human biology define our development programs that target cancer

Pipeline Overview

Our oncology pipeline is focused on restoring and bolstering immune responses and includes TTX-030. For information about the TTX-030 Phase I/Ib trial, visit: www.clinicaltrials.gov.

TTX-030 (anti-CD39)

   

TTX-080

   

TZ-040

   

Undisclosed Programs

   

ATP and Adenosine in the Tumor Microenvironment

Tumors employ various strategies to create an environment that reduces the immune system’s ability to detect and fight cancer. The ATP-adenosine pathway regulates the tumor microenvironment (TME) that both stimulates the immune system and counters immune suppression. Tizona’s TTX-030 prevents the formation of immune suppressive extracellular adenosine and maintains high levels of extracellular ATP, stimulating dendritic and myeloid-derived cells necessary for both innate and adaptive immunity.

TTX-030, a Novel First-in-Class Anti-CD39 Antibody

TTX-030 is an antibody that inhibits the activity of CD39, an enzyme that converts ATP to AMP, the initial steps in the generation of adenosine in the tumor microenvironment. Phase I/Ib clinical testing began in March 2019 evaluating TTX-030 in combination with an approved anti-PD-1 immunotherapy and in combination with standard chemotherapies in adults with advanced cancers.